Study Flags ADAMTS8 and IL6R as Aneurysm Targets
Researchers used genetic analysis to identify two candidate therapeutic targets for aortic aneurysm, with further validation still needed.
Updated on Nov. 22, 2026 in Life Sciences

A two-sample Mendelian randomisation analysis of 5,900 potentially druggable genes identified ADAMTS8 and IL6R as candidate therapeutic targets for aortic aneurysm. The analysis relied on genetic variants linked to gene expression in blood and arterial tissues.
Why it matters
Aortic aneurysm is a serious condition with few pharmacological options, so identifying candidate targets offers a potential starting point for new treatments. The findings remain preliminary and require experimental and clinical validation before any therapeutic application.
The evidence comes from a genetic association analysis rather than a clinical trial, with coronary atherosclerosis explaining about 10% and high-density lipoprotein 2.5% of the IL6R-aneurysm link. None of the 10 nominally associated tissue regions survived correction for multiple testing, leaving the causal role of these targets unconfirmed.
The details
Researchers combined genetic variants associated with gene expression in blood and arterial tissue with protein quantitative trait locus analyses, summary-data-based Mendelian randomisation, heterogeneity testing and Bayesian co-localisation. The work also identified four compounds linked to both targets: cyclopenthiazide, primaquine, decitabine and progesterone.
The Big Picture
The study applies two-sample Mendelian randomisation, a genetics-based method widely used to prioritise drug targets, to aortic aneurysm for the first time in this analysis. It follows a growing pattern of using human genetic evidence to narrow large candidate-gene lists before costly experimental work begins.
Any treatment built on these targets is years away, since the findings must first be confirmed in laboratory and clinical studies. For now, the research mainly guides which proteins scientists may prioritise for future drug development.
The takeaway
Genetic analysis can narrow large lists of possible drug targets, but a candidate gene is only a starting point. Readers should treat these aneurysm findings as hypotheses that await experimental and clinical confirmation.
Further reading
Explore more research in Life Sciences for context on how genetic evidence is used to find new drug targets.
Source note: This article includes information reported by European Medical Journal.



